FibroGen, Inc. and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease
12/12/2012 9:26:14 AM
More...
|
FibroGen, Inc. Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients
11/5/2012 9:58:21 AM
More...
|
FibroGen, Inc. Announces Results Showing That FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Corrects Anemia Without Intravenous Iron Supplementation in Incident Dialysis Patients
11/5/2012 9:56:59 AM
More...
|
FibroGen, Inc. to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology Kidney Week 2012
11/1/2012 8:31:35 AM
More...
|
FibroGen, Inc. Announces Presentation of Updated Results at European Respiratory Society Annual Congress
9/5/2012 10:03:41 AM
More...
|
FibroGen, Inc.’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients With Idiopathic Pulmonary Fibrosis
7/31/2012 9:58:22 AM
More...
|
FibroGen, Inc. Announces Preliminary Clinical Findings on the Positive Effects of FG-4592, Its Investigational HIF-PHI Therapy for Anemia, on Lowering Blood Pressure and Cholesterol in Patients With Chronic Kidney Disease
6/4/2012 10:23:43 AM
More...
|
FibroGen, Inc. Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
5/3/2012 10:29:06 AM
More...
|
FibroGen, Inc. Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals With Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
5/3/2012 8:18:02 AM
More...
|
FibroGen, Inc. Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia Correction and Maintenance in Chronic Kidney Disease Patients
11/15/2011 7:45:56 AM
More...
|
|